Summit Therapeutics Inc 뉴스 - SMMT | 주식 나스닥

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase...

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit Compared to Monotherapy Pembrolizumab in HARMONi-2 Trial Conducted by Akeso...

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive...

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

Ivonescimab Monotherapy Achieved Statistically Significant & Clinically Meaningful Improvement over Pembrolizumab Monotherapy Head-to-Head in...

👍️0

TechandBio 6 일 전

Added 10k today at 21.00 all bet on Duggan anytime! This drug is superior to Keytruda

$SMMT

👍️0

TechandBio 2 주 전

Always early still holding the 5.00's got to see the angles before they are played.

Short % of Float (1/31/2025) 17.55%

+319.06%

$SMMT

👍️0

TechandBio 3 주 전

Adding some more soon!

Founder is a legend in Biotech the man is worth 15 Billion personally for a reason!

$SMMT

👍️0

TechandBio 3 주 전

Should double from here next 12-24 months. playing some options pretty far out.

$SMMT

👍️0

TechandBio 4 주 전

Started buying this around $5.00 last year!

$SMMT

👍️0

PonkenPlonken 3 월 전

super stuff for SMMT:
https://finance.yahoo.com/news/biontech-acquire-biotheus-boost-oncology-114500977.html

now who can swallow SMMT?! They all missed this when the time was ripe- thats for sure.

👍️0

TechandBio 4 월 전

PCYC sold for 21 Billion in 2015 went from under a dollar to over 250.00 I believe $50.00-100.00 range for SMMT I can't see Robert Duggan holding on to Summit hes getting old 80+ years old. I believe a buyout happens sooner than later. Merck should buy before
another company does!

https://finance.yahoo.com/news/mrk-stock-dips-smmts-cancer-141100565.html

$SMMT

👍️0

TechandBio 4 월 전

I can't believe this stock was a $1.00 and change this year always buy the fear and make the big $

My mid cap buyouts are SMMT and Viking in 2025

$SMMT

👍️0

TechandBio 5 월 전

Added 3k pre market this is one I decided to add up on and keep buying till buyout!
Executive team means everything in Biotech.
$SMMT

👍️0

axelvento 5 월 전

Summit's focus over the next three years or so will be to wrap up its two late-stage clinical programs for treating certain patient populations with advanced or metastatic non-small cell lung cancer (NSCLC) in combination with other treatments like chemotherapy and attempt to get regulators on board with commercializing them.

One of the trials is slated to end in late 2025, and the other is scheduled to conclude in late 2027. If the Food and Drug Administration (FDA) staff assent to either program, it'll mark the first time that the biotech will have an opportunity to generate revenue from sales of a medicine, which will be a major achievement.

👍️0

TechandBio 5 월 전

Merck should buy Summit before someone else comes along and pulls the trigger before them. Duggan is well in his 90's now I would think a buyout is being discussed with a handful of blue chip Biotech companies. If Keytruda is producing 25 Billion in Revenue whats Summit worth?

$SMMT

👍️0

TechandBio 5 월 전

Regarding Lung Cancer Tumors treatments IceCure has a 77% Complete Response rate Compared to 50% for Summit vs 38% Mercks Keytruda for Lung Cancer
SMMT moved 3300% low to high this year.

https://www.icecure-medical.com/clinical-applications/lung-cancer/

IceCure has even better data for Breast Cancer 97% after 5 years and Kidney Tumors and Liver Tumors over 90% CR Rate.

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

https://www.prnewswire.com/news-releases/icecures-ice3-5-year-trial-results-published-in-the-peer-reviewed-annals-of-surgical-oncology-journal-prosense-cryoablation-without-excision-for-early-stage-low-risk-breast-cancer-demonstrates-96-3-recurrence-free-rate-302256863.html

Holding my SMMT shares under 8.00 holding for Buyout.

$SMMT

👍️0

TechandBio 5 월 전

up 200% on SMMT and adding shares on ICCM every day. Founder Victor Lee of Tencent owns 55% of Icecure shares similar to Duggan at SMMT who owns a majority of SMMT shares.
Interesting Cancer Platform Remember SMMT was a $1.00 early this year ICCM has 5 year data by half a dozen countries running independent studies safer have less side affects and much better efficacy than medicine on the market today. IceCure Freezes and Kills Tumors across the board Breast, Kidney and Lung Tumors.
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
The study titled "Liquid Nitrogen-Based Cryoablation: Complication Rates for Lung, Bone, and Soft Tissue Tumors" was published by Oxford University Press on behalf of the British Institute of Radiology.
https://ir.icecure-medical.com/news-events/press-releases/detail/144/study-published-in-the-british-journal-of-radiology-demonstrates-icecures-prosense-is-a-safe-procedure-with-97-7-technical-success-rate-in-treating-tumors-of-the-lung-bone-and-soft-tissues
FDA Panel Meeting soon and FDA Approval slated for December 20024 or January 2025 for Breast Cancer.

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
https://ir.icecure-medical.com/news-events/press-releases/detail/139/icecures-prosense-destroyed-100-of-breast-cancer-tumors-in-independent-study-of-patients-who-chose-cryoablation-instead-of-surgery

SMMT market cap 20 Billion SMMt was under a Billion market cap earlier this year.
IceCure ICCM 30 Million market cap

$SMMT

👍️0

TechandBio 5 월 전

Looking good! upside is tremendous! $100.00 Target
always early!
$SMMT

👍️0

axelvento 5 월 전

his Company Generates No Revenue and Its Market Cap Is Over
18.B

RELAX$$$$$

👍️ 1 😀 1

TechandBio 5 월 전

$SMMT was a dollar ICCM is .69 kills cancers across many indications including breast and lung cancers no side effects no IV no pills a platform that kills cancer by freezing it multiple studies done independently with 5 year data with 97% success rate 5 years out.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

👍️0

TechandBio 5 월 전

100 Billion market cap is coming as more data comes in on multi faceted oncology platform. Safer and more effective than standard of care.

$SMMT

👍️0

nsomniyak 5 월 전

The price they got and the fact that insiders took a majority of the shares are both big positives on this financing.

👍️0

Monksdream 5 월 전

SMMT new 52 week high

👍️0

Awl416 5 월 전

Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement

$235 Million in Net Proceeds Raised at Yesterday’s Closing Price of $22.70

👍️0

Invest-in-America 6 월 전

But THANKS for edifying me as to WHY the (so-called) LEGENDARY NVDA's stock price is a paltry $106 bucks!! But heck, if they do a generous FORWARD-Split, maybe they can drop that price down to just $16 bucks!!! With a total FLOAT of circa 2.5-TRILLION shares!!!

Invest-in-America 6 월 전

It's big, which held it DOWN somewhat --- but I still LIKE this firm.

👍️0

retireat40 6 월 전

Big float? It’s only 96 million. NIO had a good run today and their float is 1.2 billion. NVDA has a float of 23.5 billion. You’re crazy if you think this has a large float.

👍️0

Invest-in-America 6 월 전

SMMT: Not quite the $50, or so, that I had guessed might happen today. (But I still don't think the IMPACT of their news is over yet; despite the big stock FLOAT of this curious Firm.)

Invest-in-America 6 월 전

👍️0

Invest-in-America 6 월 전

SMMT: Nevertheless, very LIKELY hits $40-$50 bucks a share today.

👍️0

TheFinalCD 6 월 전

new highs https://ih.advfn.com/stock-market/NASDAQ/summit-therapeutics-SMMT/stock-news/94513885/form-8-k-current-report

👍️0

Invest-in-America 6 월 전

SMMT: Watch out for that 95-million FLOAT!! (Nice news, though.)

BINGO- Summit lung cancer drug shows ‘striking’ benefit over Keytruda

https://finance.yahoo.com/news/summit-lung-cancer-drug-shows-113800395.html

I sold 1/2 my position around $9 anticipating a drop down to $5.85 which is where I placed limit order which never filled. I put some of the gains into VolitionRX VNRX @ $0.80 and added to that position when it dropped to $0.65. Liquid biopsy is getting attention of VC's in silicon valley. I see a future where early cancer diagnosis is treated with Ivonescimab. VNRX has a vet product on the market by the way. I think the SMMT collaboration with MD Anderson is brilliant and shows what leadership is all about.

👍️0

TechandBio 8 월 전

I have been Following Duggan since for the last 25 years made my first big win pcyc buying for dollars and waking up to a $261.00 share price a decade ago I also got into $PLSE a few years ago when it went to 1.30-1.40 range still holding a modest position. It looks like the drug that Summit has Ivonescimab works better then Keytruda in some cancer indications. Holding my 10k shares of SMMT at 2.25 wish I bought more and bought some options. I think we could see another buyout possibly by Merck. This company IceCure ICCM is showing incredible data with 5 year follow up on early breast cancer patients and killing 97% of tumors in breast cancer patients and even killing 92% of tumors in later stage breast cancer patients with larger tumors and feedback from patients and doctors is 100% They also have data showing best in class data for Kidney, Bone and Lung Cancer. Their cryoblast is approved in 15 countries and starting to build some revenue. Most striking about the technology it can be done in less than hour in patient setting with local anesthetic with the patient being able to go back home within hours and getting right back to their routine I could see the stock going over $10.00 1300% return.
$SMMT

👍️0

Rayn_Makr 8 월 전

Watching the trades on Fidelity active trader pro today, Friday 6/21/24, at 16:00:00 one trade shows up. Volume = 5,808,156 at a price of $7.93 for a total of $46,058,677.08. So 2.2 million in the first 6.5 hours and 5.8 million in one second at exactly 4 pm. I called Fidelity ATP support and they confirm that this is accurate data. It also appears on Yahoo Finance and Finviz. 8.1 million shares traded today. Gotta be short covering. I have never seen anything like this before today. Be great if short sellers were gone, eh?

👍️0

Rayn_Makr 8 월 전

Watching the trades at the close yesterday, Wednesday 6/12/24, and in the final 15 sec, 502,000 shares @ $8.22 = $4,126,440. Short covering or tute buying in? IDK but I'm thinking this is a market order that gets filled without moving the price. Big money is all I know and it caught my interest. Thought it supports the current price.

Thanks for the link axel.

👍️0

axelvento 9 월 전

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news

https://www.biotechtv.com/post/summit-therapeutics-june-1-2024

$HUGE

👍️0

JFR161162 9 월 전

I meant NWBO pre opening trades
Wrong board sorry

👍️0

JFR161162 9 월 전

I see 2 pre opening trades this morning.

1,400 shares at $,4816
5,100 shares at $,50

Here's the link to the JAMA publication: https://jamanetwork.com/journals/jama/fullarticle/2819600
I've spent the afternoon reading it a couple times and here's my $0.02 worth.

The P-values on all the stats are very impressive. The efficacy was P<0.001. Responce rate, ORR, had P<.0.006. "Significant longer PFS duration than chemotherapy alone" was P<0.001. All of these are less than the P<0.05 that is the typical value required. If the Summit P3 trials are still recruiting I would expect there would be considerable effort to get enrolled if you are diagnosed with this type of CA.

I have also seen P3 trials ended early due to ethical considerations but whether or not that applies here is way beyond my pay grade as they say. Frankly, I would struggle with continuing to let the group not receiving Ivonescimab progress their treatments knowing what we know now. Safe to assume that the FDA will require a complete study and analysis. I hope it goes to market quickly which will benefit millions.

👍️0

Rayn_Makr 9 월 전

Lots of news regarding ASCO, an article published in JAMA (which is no small feat since it is THE JOURNAL of....), conference call Monday, 6/3/24, @ 8 am. Refer to Summit website for the folowing press release.

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024
Conference Call to be Held at 8:00am ET on Monday, June 3, 2024

👍️0

Termite7 9 월 전

Why the HUGE gap up? ...Thanks!!!

👍️0

Rayn_Makr 9 월 전

If I were to hazard a guess..... Recruiting a person with FDA submissions experience since that will be the next hurdle. You know, get it right the first time and avoid timely delays, resubmissions etc.

👍️0

Rayn_Makr 9 월 전

This looks like a typical recruitment tool to bring a "heavy hitter" on board. Four years to vest so it keeps them around. It is a common retention tool and a nice feature to have in your employment agreement. It can turn out to be worth considerably more than your salary.

👍️0

Invest-in-America 9 월 전

SMMT: But what about THIS (later) news today??? ----
https://finance.yahoo.com/news/summit-therapeutics-reports-inducement-grants-220000000.html

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Summit Therapeutics Inc (SMMT)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

SMMT 뉴스

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

Form D - Notice of Exempt Offering of Securities

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

SMMT Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Summit Therapeutics Inc (SMMT) 뉴스

Summit Therapeutics Inc (SMMT)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

SMMT 뉴스

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

Form D - Notice of Exempt Offering of Securities

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

SMMT Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거